Article Sidebar
Main Article Content
Abstract
Background: The rise of Methicillin-Resistant Staphylococcus aureus (MRSA) in surgical site infections necessitates the development of non-resistant therapeutic adjuvants. Syzygium aromaticum (Clove) possesses known antimicrobial properties, yet its specific immunomodulatory effects on the MRSA-induced cytokine storm and wound chronicity remain under-characterized. This study investigated the efficacy of a standardized ethanolic extract of S. aromaticum flower buds in modulating the inflammatory milieu and accelerating wound repair.
Methods: A true experimental study was conducted using 30 male Wistar rats with MRSA-infected dorsal excision wounds. Subjects were randomized into six groups (n=5): Normal Control (K1), Negative Control (MRSA+Vehicle, K2), Positive Control (MRSA+Vancomycin, K3), and treatment groups receiving 25 mg (P1), 50 mg (P2), and 100 mg/200g BW (P3) of extract orally for 10 days. The extract was characterized via HPLC. Serum TNF-α, CRP, and IL-10 were quantified by ELISA. Secondary outcomes included bacterial load reduction and macroscopic wound contraction rates.
Results: HPLC analysis confirmed eugenol (68.4%) and β-caryophyllene (12.1%) as major constituents. MRSA infection (K2) provoked a severe inflammatory state (TNF-α: 17.92 ± 0.42 pg/mL; IL-10: 110.21 ± 2.72 pg/mL). The 100 mg extract dose (P3) significantly suppressed TNF-α (7.40 ± 0.48 pg/mL, p<0.001) and normalized IL-10 (49.92 ± 2.56 pg/mL), demonstrating non-inferiority to Vancomycin (p=1.000). Bacterial load was reduced by 4 log units (1.2 × 10³ vs 5.8 × 10⁷ CFU/g).
Conclusion: Standardized S. aromaticum extract functions as a potent immunomodulator, resolving MRSA-induced inflammation by balancing pro- and anti-inflammatory cytokines, thereby facilitating the transition from the inflammatory to the proliferative phase of healing.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
